Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: )-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible, HER2-selective tyrosine kinase inhibitor that has been shown to have efficacy in persons with advanced or metastatic solid tumors with HER2 alterations in a phase 1 study. METHODS: -mutant NSCLC. Here we report the primary analysis of zongertinib in previously treated patients: those with tumors harboring a mutation in the tyrosine kinase domain (cohort 1), those with tumors harboring a mutation in the tyrosine kinase domain previously treated with a HER2-directed antibody-drug conjugate (cohort 5), and those with tumors harboring a non-tyrosine kinase domain mutation (cohort 3). In cohort 1, patients were initially randomly assigned to receive zongertinib at a dose of 120 mg or 240 mg once daily. Patients in cohorts 5 and 3 initially received 240 mg daily. After an interim analysis of data from cohort 1, subsequently recruited patients across all cohorts received zongertinib at a dose of 120 mg. The primary end point was an objective response assessed by blinded independent central review (cohorts 1 and 5) or by investigator review (cohort 3). Secondary end points included the duration of response and progression-free survival. RESULTS: In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg. At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0.001 against a ≤30% benchmark) had a confirmed objective response; the median duration of response was 14.1 months (95% CI, 6.9 to not evaluable), and the median progression-free survival was 12.4 months (95% CI, 8.2 to not evaluable). Grade 3 or higher drug-related adverse events occurred in 13 patients (17%). In cohort 5 (31 patients), 48% of the patients (95% CI, 32 to 65) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 1 patient (3%). In cohort 3 (20 patients), 30% of the patients (95% CI, 15 to 52) had a confirmed objective response. Grade 3 or higher drug-related adverse events occurred in 5 patients (25%). Across all three cohorts, no cases of drug-related interstitial lung disease occurred. CONCLUSIONS: -mutant NSCLC. (Funded by Boehringer Ingelheim; Beamion LUNG-1 ClinicalTrials.gov number, NCT04886804.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Self-citationNon–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
Self-citationRobichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Self-citationZhou, C., Li, X., Wang, Q., Gao, G., Zhang, Y., Chen, J., Shu, Y., Hu, Y., Fan, Y., Fang, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00297 · Cited by 205
Riudavets, M., Sullivan, I., Abdayem, P., & Planchard, D. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100260 · Cited by 196
Self-citationLe, X., Cornelissen, R., Garassino, M., Clarke, J. M., Tchekmedyian, N., Goldman, J. W., Leu, S.-Y., Bhat, G., Lebel, F., Heymach, J. V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01323 · Cited by 160
Self-citationMechanisms of Resistance to Antibody-Drug Conjugates
Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., & Lecesne, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119674 · Cited by 159
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Gibbons, D. L., Fossella, F. V., Lam, V. K. L., Patel, A. B., Negrao, M. V., Le, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01113 · Cited by 109
Self-citation
Cited by
Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology
Riely, G. J., Wood, D. E., Aisner, D. L., Axtell, A. L., Bauman, J. R., Bharat, A., Chang, J. Y., Desai, A. P., Dilling, T. J., Dowell, J. E., et al. (2026) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2026.0017 · Cited by 93
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Le, X., Kim, T. M., Loong, H. H., Prelaj, A., Goh, B. C., Li, L., Fang, Y., Lu, S., Dong, X., Wu, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511065 · Cited by 70
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Roskoski, R. J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108107 · Cited by 61
Janne, P. A., Goto, Y., Kubo, T., Ninomiya, K., Kim, S., Planchard, D., Ahn, M., Smit, E. F., Langen, A. J. D., Pérol, M., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.129 · Cited by 44
Self-citationPuri, S., Leighl, N. B., Ismaila, N., Rous, F. A., Ahluwalia, A., Alluri, K. C., Azar, I. H., Campbell, T., Durm, G. A., Feldman, J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02822 · Cited by 46
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Siegel, F., Siegel, S., Kotýnková, K., Uzunbas, G. K., Korr, D., Tomono, H., Andersen, S., Denney, D. R., Berger, M., Schulze, V., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0605 · Cited by 37
“Although T-DXd and zongertinib have received accelerated approval for the treatment of patients with NSCLC with HER2 exon 20 insertions (25), there is still a need for active and well-tolerated oral therapies for these patients.”
InfluentialIsmail, A., Desai, A. P., & Boumber, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1624124 · Cited by 36
“Such drugs include poziotinib, tarloxotinib, mobocertinib, zongertinib, and others (Table 1) (11, 50 – 67).”
InfluentialAliaga, P. T., Spitaleri, G., Attili, I., Corvaja, C., Battaiotto, E., Angelopoulos, P. A., Signore, E. D., Passaro, A., & de Marinis, F. (2025) · Molecules · doi:10.3390/molecules30122645 · Cited by 27
“No cases of drug-related interstitial lung disease (ILD) occurred in all three cohorts [78].”
Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.01.007 · Cited by 25
Self-citationFirst-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Heymach, J. V., Yamamoto, N., Girard, N., Ruiter, G., Smit, E. F., Planchard, D., Nadal, E., Wu, Y.-L., Zugazagoitia, J., Tu, H., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2516969 · Cited by 23
Self-citationAdvances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 21
Precision Oncology: 2025 in Review
Mai, N., Fernandez, N. C., Drilon, A. E. D. C., & Chakravarty, D. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1784 · Cited by 18
The development of Zongertinib for HER2-mutant NSCLC
Brazel, D., Park, C. J., & Nagasaka, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104896 · Cited by 13
Illini, O., Hund, A.-C., Kopp, H., Moskovitz, M. T., Mountzios, G., Brueckl, W. M., Früh, M., Leßmann, M.-E., Christopoulos, P., Stenzinger, A., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103651 · Cited by 9
Lee, A. (2026) · Drugs · doi:10.1007/s40265-025-02265-y · Cited by 8
Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer
Ekyalongo, R., Yamaoka, T., & Tsurutani, J. (2025) · Biomolecules · doi:10.3390/biom15101443 · Cited by 7
“Moreover, patients with ERBB2 -mutated NSCLC who had received a HER2-targeted ADC demonstrated an ORR of 48% [66].”
Zhou, H., Zhao, H., Hou, X., Wang, Y., He, Z., Li, Y., Ma, Y., Zhao, Y.-H., Huang, Y., Chen, L., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01929 · Cited by 7
“11 ,26 In the DESTINY-Lung02 trial, T-DXd demonstrated an ORR of 55%.”
Self-citationHurvitz, S. A., Simonelli, M., Yarza, R., Berz, D., Kitano, S., Conte, G. D., Acosta-Eyzaguirre, D., Uribe, B. D. D. S., Maier, D., Eržen, D., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2569553 · Cited by 7
“In an ongoing Phase Ia/Ib trial (NCT04886804), zongertinib demonstrated potent activity and a manageable safety profile in patients with previously treated, HER2-altered, advanced solid tumors (Phase Ia) [37–39] and HER2-mutant non-small cell lung cancer (NSCLC; Phase Ib) [40].”
InfluentialA comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
Bai, Y., Li, R., Zhang, X., Seng, D., Xu, Y., Zhang, S., & Yuan, S. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2704735 · Cited by 6
“in August 2025, the U.S. FDA announced the accelerated approval of zongertinib for marketing, specifically for the treatment of NSclc patients carrying human eGFR 2 (HeR2) tyrosine kinase domain (tKD) activated mutations 71 .”
Pereira, H., Wölke, S., Sadrolhefazi, B., Esmaeili, H. A., Wind, S., Gan, G., Müller, F., Minich, D., Bader, K., Grempler, R., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00832 · Cited by 6
Self-citationAbbas, M., Sami, S. H. A., Gajdács, M., & Tariq, M. J. (2025) · EXCLI journal · doi:10.17179/excli2025-8972 · Cited by 5
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M. M., Helyes, Z., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R., Patel, H. H., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70376 · Cited by 5
Evolving treatment strategies for HER2-altered non–small-cell lung cancer: the rise of TKIs and ADCs
Ballı, S., Başoğlu, T., & Ozdogan, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1771869 · Cited by 5
“More recently, the development of HER2-selective TKIs and next-generation ADCs has supported a more integrated role for systemic therapies alongside local approaches (128).”
Stockhammer, P., Zarif, T. E., Schillo, J. L., Li, F., Goldberg, S. B., Politi, K. A., & Grant, M. J. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103708 · Cited by 5
Emerging Targeted Therapies for HER2-Mutant NSCLC
Rio, B. D., Masini, S., Cáceres-Galvis, C., Torres-Jiménez, J., Bote, H., Berjaga, M. Z., Baena-, J., Serrano, C., Nuñez, J. A., Ponce-Aix, S., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103899 · Cited by 5
Self-citationSynthesis and Clinical Application of Small‐Molecule Drugs Approved by FDA in 2025
Chang, L., Wang, M., Zhang, H., Li, Z., Song, Z., Zhao, L., Jiang, F., Wang, J., & Yuan, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70064 · Cited by 5
Targeted Therapies in Non–Small Cell Lung Cancer: A Contemporary Review
Abdelmonem, A., Bikram Shah, B., Shebli, M. A., & Tabbara, I. A. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001275 · Cited by 4
Huang, K., Hu, Z., Pan, S., Jialin, Q. I. A. N., Wu, X., Wang, H., Wang, K., Lu, H., Dong, H., Chu, T., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-916 · Cited by 4
“…LUNG-1 trial showed a median PFS of 12.4 months and an ORR of 71% with zongertinib (a HER2-TKI) in patients with previously treated advanced NSCLC harboring a HER2 mutation in the tyrosine kinase domain (12), which has been approved by FDA and has become another preferred option besides T-DXd (13).”
InfluentialWinslow, M. M., Ahmed, M. A., Berg, C. D., Black, J. R., Downward, J., Govindan, R., Herbst, R. S., Heymach, J. V., Jaffee, E. M., Kraut, N., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2318 · Cited by 4
Self-citationElzaafarany, O. H. (2025) · Cureus · doi:10.7759/cureus.88905 · Cited by 3
“However, its efficacy in the subset of patients with LMD is lacking [8].”
Haider, E., Ahmad, N., Taj, J., & Ekouo, J. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004571 · Cited by 3
“In the Beamion LUNG-1 trial, a pivotal phase II/III study, Zongertinib achieved an objective response rate above 50%, median progression-free survival near 8 months, and meaningful intracranial activity in HER2-mutant NSCLC that had failed chemotherapy or immunotherapy [ 5 ] .”
Heymach, J. V., Popat, S., Smit, E. F., Christopoulos, P., Planchard, D., Yoshida, T., Zugazagoitia, J., Yu, Y., & Wilding, B. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2623059 · Cited by 3
Self-citationHER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape
Muscolino, P., Fassi, E., Signorelli, D., Colonese, F., Cortinovis, D. L., Russo, G. L., Pasello, G., Infurna, C., Ciappina, G., Berretta, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052334 · Cited by 3
Ikushima, H., Motomura, H., Watanabe, K., Shinozaki-Ushiku, A., Oda, K., & Kage, H. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01447-5 · Cited by 3
“The study reported differences in ef fi cacy based on mutation location, with zongertinib achieving an objective response rate of71%inpatientsharboringkinasedomainmutations,comparedwithonly 30%inthosewithnon-kinasedomainalterations 28 .”
Parisi, C., Barlési, F., & Planchard, D. (2026) · Cancer · doi:10.1002/cncr.70422 · Cited by 3
“20 Traditional HER2 - targeted therapies have shown limited efficacy in HER2 - altered NSCLC, although this is likely to change in the near future with the arrival of new - generation HER2 - TKIs, such as zongertinib, 21 underscoring the need for innovative therapeutic approaches.”
Self-citationExpanding targeted therapy for lung cancer
Ballard, W., Agarwal, M., & Liu, S. V. (2025) · Nature Cancer · doi:10.1038/s43018-025-01083-1 · Cited by 2
Latli, B., & Chong, E. (2025) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.4168 · Cited by 2
Yasuda, Y., Hattori, Y., & Satouchi, M. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6445-25 · Cited by 2
“Currently, HER2-targeted agents such as zongertinib have demonstrated promising antitumor activity in clinical trials (20).”
Oral TKI zongertinib gains accelerated approval for HER2 ‐mutant NSCLC
Lawrence, L. (2025) · Cancer · doi:10.1002/cncr.70145 · Cited by 2
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer
Fortman, D. D., & Qin, A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1750153 · Cited by 2
Fu, W., Zou, X., He, T., Cai, Q., Chen, P., Cheng, B., Feng, Y., Li, C., Li, F., Li, J., et al. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-1-1477 · Cited by 2
Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer
Kim, J., & Ahn, M. (2026) · Future Oncology · doi:10.1080/14796694.2026.2658641 · Cited by 2
Self-citationMavrikios, A., Bortolot, M., Pechoux, C. L., Remón, J., Botticella, A., Aldea, M. D., Brown, P. D., Rusthoven, C. G., Lavaud, P., Frélaut, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.014 · Cited by 2
Self-citationReal-world effectiveness of molecular-matched therapies in salivary gland cancer
Weijers, J. A. M., van Ruitenbeek, N. J., Grunsven, A. C. H. V. E., Driessen, C. M. L., Devriese, L. A., Slingerland, M., Hoeben, A., Oosting, S. F., Schreuder, W. H., Sewnaik, A., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106961 · Cited by 2
“41 These findings prompt investigation of trastuzumab — deruxtecan and zongertinib in HER2-low expressing and ERBB2 -mutant SDC.”
New drugs approved by the FDA in 2025: Synthesis and clinical applications
Liu, W., Li, X., Han, Y., Wu, L., Wang, M., Xuan, W., Xu, Z., Liu, W., Zhao, Q., & Hao, S. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118952 · Cited by 2
Recent advances in HER2-targeted inhibitors for cancer therapy
Zhu, W., & Lu, X. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100127 · Cited by 2
“In patients with HER2 kinase domain mutations, the confirmed objective response rate was 71%; the median duration of response and PFS were 14.1 and 12.4 months, respectively [53].”
InfluentialLovly, C. M., Baik, C., Nagasaka, M., Patil, T., Maruti, S. S., Stanhope, S. A., Kaya, N. A., Herbertz, S., Nordstrom, B., Evans, K., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01272 · Cited by 2
“15,17 Zongertinib is also approved in China (conditional) and Japan for patients with previously treated advanced/metastatic HER2 -mutant NSCLC. 19-30 However, some lacked detailed genomic pro fi ling, assessment of clinical outcomes according to line of treatment (LOT), and survival data.”
Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
Hendriks, L. E. L., Lin, J. J., Tan, D. S. W., Acker, F., Ogliari, F. R., Meyer, M., Planchard, D., & Reck, M. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00253-5 · Cited by 2
Self-citationPromising results with zongertinib in advanced-stage HER2-mutant NSCLC
Romero, D. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01030-0 · Cited by 2
Wölke, S., Sadrolhefazi, B., Esmaeili, H. A., Wind, S., Blattner, S. M., Gan, G., Qiang, D., Schirmer, A., & Müller, F. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00831 · Cited by 2
Self-citationGrempler, R., Joseph, D. P., Gan, G., Auclair, A., Tiessen, R. G., Maw, H. H., Laux, R., Wind, S., Roessner, P. M., Sadrolhefazi, B., et al. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01509-9 · Cited by 1
Self-citationKey Update in 2025 Japanese Lung Cancer Society Guidelines
Omori, S., Ninomiya, K., & Takahashi, T. (2025) · Haigan · doi:10.2482/haigan.65.847 · Cited by 1
Tregel, E., Rieke, D. T., Bleckmann, A., Westphalen, C. B., Pretzell, I., Lange, S., Quante, M., & Kloker, L. D. (2026) · Oncology Research and Treatment · doi:10.1159/000551042 · Cited by 1
Targeted therapies in lung cancer: personalizing treatment across the age spectrum
Xu, Y., Chen, F., Zhang, H., & Wang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1743620 · Cited by 1
Ghosh, I., Sharma, P., & Ghosh, A. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1817161 · Cited by 1
Schram, A. M., Park, J., Italiano, A., Kitano, S., Guo, Y. P., Li, J., Bedard, P. L., Marcke, C. V., Ko, R., Lunger, L., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2637740 · Cited by 1
“The recent accelerated approval in the United States was based on data from the Phase Ia/Ib Beamion LUNG-1 trial (NCT04886804), where zongertinib mono-therapy demonstrated clinically meaningful efficacy in previously treated patients with HER2-mutant NSCLC [16].”
InfluentialSelf-citationKatsuya, Y., Koyama, T., Sato, J., Okada, M., & Yamamoto, N. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2026.100692 · Cited by 1
Self-citationRuiter, G., Le, X., Soo, R. A., Yamamoto, N., Girard, N., Wu, Y.-L., Sabari, J. K., & Nadal, E. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109378 · Cited by 1
“However, notwithstanding these limitations, it does appear that TKIs like zongertinib and sevabertinib offer favorable response rates (~65 – 70%), [71,77] higher than that observed with T-DXd (~50 – 55”
Self-citationIshida, M., Yamada, T., Katayama, Y., Kawachi, H., Sawada, R., Nakamura, R., Hirai, S., Matsui, Y., Morimoto, K., Onoi, K., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01385-2 · Cited by 1
“Recently, the FDA approved trastuzumab deruxtecan, an antibody – drug conjugate, for patients with unresectable or metastatic HER2-positive solid tumors 30 .”
InfluentialHarada, G., Chaft, J. E., Schram, A. M., Pavlakis, N., & Wu, Y.-L. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103137 · Cited by 1
Self-citationTanvetyanon, T., Chen, D.-T., & Gray, J. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093481 · Cited by 1
Goto, K., Hayashi, H., Maruti, S. S., Zettl, H., Mittal, L., Pathak, S., & Le, X. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01213-4 · Cited by 1
“In 2025, the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib [10–12], and the HER2/EGFR TKI, sevabertinib [13, 14], received FDA accelerated approval on the basis of the Beamion LUNG-1 and SOHO-01 trials [10, 14].”
Nagl, L., Horvath, L., Amann, A., Schreiner, L., Günther, M., Maier, H., Kerschbaumer, J., Widmann, G., Minasch, D., Rossetti, L.-M., et al. (2026) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2026.101023 · Cited by 1
HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC)
Meinhardt, F. W. R., Iglesias, M. I. Z., Gómez, M. P. F., Fonseca, J. F. S., Hussein, A., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114910 · Cited by 1
“Zongertinib is an orally administered, irreversible TKI that selectively targets HER2, including exon 20 insertions, avoiding wild-type EGFR, helping to minimize target toxicities [11,14,52].”
InfluentialERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers
Shreenivas, A. V., Elliott, A., Corbiere, T. F., Chen, H.-Z., George, B., Kamgar, M., Chakrabarti, S., Desai, A. P., Bracken-Clarke, D. M., Xue, E., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.107772 · Cited by 1
“13 46-49 Moreover, HER2 expression is heterogeneous, 50,51 changing over time and by site of recurrence or metastasis, 52,53 and understanding these fluctuations is crucial across multiple cancer subtypes.”
Yan, W., Liu, C., Li, T., Hu, Y., & Zhao, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1832498 · Cited by 1
“Recent data demonstrate that zongertinib achieves clinically meaningful responses in previously treated HER2 − mutant disease, supporting its role as a next − line targeted option (24).”
Yoshimura, A., Yoshida, J., Takumi, C., & Takayama, K. (2026) · Cancer Science · doi:10.1111/cas.70504 · Cited by 1
Small-Molecule Drugs Approved by the FDA in 2025
Wang, X., Wang, Y., Luo, R., 牛东海, Yang, L., & Wang, Z. (2026) · Molecules · doi:10.3390/molecules31193447 · Cited by 1
Updates in HER2 (ERBB2)-Mutant Advanced NSCLC: Clinical and Functional Outcomes
Evangelou, C. (2025) · doi:10.33590/oncolamj/ktpl8927 · Cited by 1
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
Wu, L., Yu, J., & Liu, W. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2517517 · Cited by 1
Singh, P. K. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103577 · Cited by 1
Nierengarten, M. B. (2025) · Cancer · doi:10.1002/cncr.70076
Cancer bronchique non à petites cellules avec autres mutations actionnables (BRAF, MET, HER2)
Mogenet, A., Cortot, A. B., Abdayem, P., Planchard, D., & Greillier, L. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00079-5
Self-citationZhou, H., Lv, M., Li, W., Wang, Y., Wu, J., Liu, Q., Liu, T., & Li, Q. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf341
Advances in Systemic Therapy for Lung Cancer
Lalla, M., Pan, E., Jokić, V., Jeon, H., & Halmos, B. (2025) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2025.09.005
Matsumura, N., & Mandai, M. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02901-3
[Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation].
Yu, J., & Cao, B. (2025) · PubMed Central · doi:10.3779/j.issn.1009-3419.2025.106.22
“的选择性 HER2 TKI ,它能够高度特异性地抑制 HER2 信 号通路,避免对野生型 EGFR 的干扰,从而降低了 EGFR 相 关毒性反应 [46] 。 Beamion LUNG-1 研究 [29] 显示,携带 HER2 酪氨酸激酶结构域( tyrosine kinase domain, TKD )突变的 晚期 NSCLC 患者接受 Zongertinib 的 ORR 达 71% , mPFS 达”
An Update on Therapeutic Strategies for HER2-Mutated Non-Small Cell Lung Cancer
Ishihara, M., Tanzawa, S., Honda, T., Ichikawa, Y., Watanabe, K., & Seki, N. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0029
Gulden, J. (2025) · Deutsches Ärzteblatt · doi:10.3238/persesmo.2025.11.28.04
Xu, Y., Nagasaka, M., Ou, S. I., & Li, M. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.08.018
Evangelou, C. (2025) · Oncology The American Medical Journal · doi:10.33590/oncolamj/befa1660
2025 Update: Cutting-Edge Molecular Targeted Treatments
Kunimasa, K. (2025) · Haigan · doi:10.2482/haigan.65.852
Lin, J.-X., Yin, K., Yan, L.-X., Zhu, Y., Xu, B.-F., Sun, Y.-L., Wu, Y.-L., & Tu, H.-Y. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108912
Self-citationNanotechnology-Enabled Precision Therapy for Lung Cancer in Never-Smokers
Cojocaru, C., Turcanu, A., Cojocaru, R., & Cojocaru, E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020161
“As illustrated in Figure 3, the idealized core–shell architecture comprises a hydrophobic core hosting the TKI and a hydrophilic shell carrying the companion molecule.”
Zongertinib: A Novel Therapeutic Advance in HER2-Mutant Non-Small Cell Lung Cancer
Agarwal, P., Gangoda, R., Sharma, M., Somani, R., & Somani, N. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1816580
Huang, X. S., Yu, W., Li, X., Cai, B., Qu, B., Chen, J., Zhang, P., Chen, X., Liu, Y., Feng, S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1727362
Zongertinib and Sevabertinib for Her2-Mutant Non-Small Cell Lung Cancer
Sunny, G., Basu, P., & Yadav, R. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1817162
Sevabertinib zeigt Wirkung – mit Nebenwirkungen
Gillissen, A. (2026) · Pneumo News · doi:10.1007/s15033-025-4265-1
“Zongertinib mit HER2-hemmender Wirkung wiede-rum ist in den USA, nicht aber in der EU, zugelassen zur Zweit-linientherapie des fortgeschrittenen HER2-positiven NSCLC [2, 3].”
Advances in Pharmacological Treatment of Thoracic Malignancies
Shukuya, T., & TAKAHASHI, K. (2026) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0049-r
“…( BI 1810631 ) has recently emerged as a next-generation, highly selective, irreversible HER2-TKI with promising early clinical activity in HER2-mutant NSCLC, particularly exon 20 inser tions; as an oral agent, it may serve as an alterna tive or sequential option after ADCs as data mature 22 ) .”
Oral TKI sevabertinib approved for advanced HER2 ‐mutant NSCLC
Lawrence, L. (2026) · Cancer · doi:10.1002/cncr.70277
The HER2 (ERBB2) Blueprint: What ‘Activating’ Really Means
AMJ (2026) · Oncology The American Medical Journal · doi:10.33590/oncolamj/c5244jh8
Targeting Brain Metastases: Intracranial Activity of Zongertinib in HER2 (ERBB2)-Mutant NSCLC
AMJ (2026) · Oncology The American Medical Journal · doi:10.33590/oncolamj/5p3t3k5f
2024–2025 Drug Updates in Solid Tumors
Kevin Y. Chen, P. (2026) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2026.17.2.6
Trendbericht Organische Chemie 2026
Breugst, M., Andexer, J. N., Barra, L., Beil, S. B., Bierbach, S., Burkhardt, I., Dumele∞, O., Ernst, M., Frommer, J., Gellrich, U., et al. (2026) · Nachrichten aus der Chemie · doi:10.1002/nadc.20264156596
Kashizaki, F., Orii, R., Watanabe, S., & Yumoto, K. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.03.018
Fatima, F., Ahmed, M. T., Akmal, M., Ahmed, M., Aftab, Z., Ali, A., & Mirza, A. (2026) · Journal of Cancer Biomoleculars and Therapeutics · doi:10.62382/jcbt.v3i2.99
Targeting HER2 in advanced non-small cell lung cancer: The emerging role of zongertinib
Pallas, C. R., Carrizosa, D. R., & Mileham, K. F. (2026) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2026.22.1.6
Chan, J. K., Rothe, M., Garrett-Mayer, E. S., Pisick, E. P., Ghatalia, P., Gregory, A., deShazo, M., Mileham, K. F., Murphy, M. C., Alese, O. B., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01250
Metadata
- Authors
- Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., Zhao, Y., Tu, H.-Y., Yoh, K., Nadal, E., Sadrolhefazi, B., Rohrbacher, M., von Wangenheim, U., Eigenbrod-Giese, S., & Zugazagoitia, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- The Netherlands Cancer Institute (NL)
- Samsung Medical Center (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Leiden University Medical Center (NL)
- Université Paris-Saclay (FR)
- Guangdong Academy of Medical Sciences (CN)
- Yonsei University (KR)
- National Cancer Center Hospital (JP)
- NYU Langone Health (US)
- Zhengzhou University (CN)
- National Cancer Center Hospital East (JP)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim Pharma, Biberach an der Riss, Germany
- Hospital Universitario 12 De Octubre (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-19
- Volume
- 392
- Issue
- 23
- Pages
- 2321-2333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409870405
- Semantic Scholar
- a2f803e8a004efcfe20ec66609ef88935fb403da
- Cited by
- 118
- References
- 25
- Citations by year
- 2026: 84 · 2025: 34
- FWCI
- 77.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (publishedVersion)
- HAL (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- zongertinib, HER2-mutant non-small cell lung cancer, HER2 tyrosine kinase inhibitor, previously treated patients, tyrosine kinase domain mutations, objective response rate, progression-free survival, duration of response, drug-related adverse events, oral tyrosine kinase inhibitor
- MeSH terms
- Trastuzumab, Progression-Free Survival, Tyrosine Kinase Inhibitors, Adult, Aged, Aged, 80 and over, Camptothecin, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.